PI3K-mTOR

May 3, 2017May 3, 2017

EMA Grants Orphan Drug Designation for PQR309 Therapeutic In Diffuse Large B-Cell Lymphoma

News

The European Medicines Agency (EMA) has granted Swiss pharmaceutical firm PIQUR Therapeutics orphan drug designation for PQR309 to treat patients with diffuse large B-cell lymphoma (DLBCL). Claudia Pluess, the company’s senior ... Read more

June 30, 2016June 30, 2016

Survival Markedly Improved in Diffuse Large B-Cell Lymphoma with Everolimus, R-CHOP Combo Therapy

News

Combining everolimus, an inhibitor of the PI3K-mTOR pathway, with the standard R-CHOP therapy may greatly increase the cure rate of diffuse large B-cell lymphoma (DLBCL) patients who have not been previously ... Read more